Literature DB >> 26692246

Cementless total hip replacements in sickle cell disease.

Christopher M Jack1, Jo Howard1, Emad S Aziz1, Rachel Kesse-Adu1, Marcus J Bankes1.   

Abstract

BACKGROUND: Sickle cell disease (SCD) affects around 80,000 people in the USA and 12,000 in the UK. Up to 40% of patients will get osteonecrosis of the femoral head. Cemented acetabular components yield poor results with the rate of osteolysis ranging from 13.5 to 46%. We report on a consecutive cohort of patients with SCD who underwent uncemented THA with ceramic-on-ceramic (CoC) bearings.
METHODS: Since 2002 52 primary THAs were carried out in 40 patients. The average age was 36.1 years (17-54). 48 cases had exchange blood transfusion preoperatively and 3 had top-up transfusions.An S-ROM was used in 47 hips a Solutions stem in 4 hips and an AML in 1. It was necessary to drill the femur during 12 hips. There were 5 intra-operative peri-prosthetic fractures. 2 dislocations were observed. 2 superficial infections were detected.
RESULTS: All components have in-grown. There have been no cases of radiographic osteolysis, migration or loosening of the hip with average 5-year (2-10.1) follow-up.
CONCLUSIONS: The combination of a multidisciplinary team approach and uncemented implants, with ceramic-on-ceramic bearings used, has made THA in patients with SCD a safe and reliable procedure in our hospital.

Entities:  

Mesh:

Year:  2015        PMID: 26692246     DOI: 10.5301/hipint.5000317

Source DB:  PubMed          Journal:  Hip Int        ISSN: 1120-7000            Impact factor:   2.135


  7 in total

1.  Optimal disease management and health monitoring in adults with sickle cell disease.

Authors:  Jo Howard; Swee Lay Thein
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

2.  The staged management of gleno-humeral joint osteonecrosis in patients with haematological-induced disease-a cohort review.

Authors:  Toby J Colegate-Stone; Saurabh Aggarwal; Karthik Karuppaiah; Adel Tavakkolizadeh; Joydeep Sinha; Ines Lh Reichert
Journal:  Int Orthop       Date:  2018-05-11       Impact factor: 3.075

3.  American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support.

Authors:  Stella T Chou; Mouaz Alsawas; Ross M Fasano; Joshua J Field; Jeanne E Hendrickson; Jo Howard; Michelle Kameka; Janet L Kwiatkowski; France Pirenne; Patricia A Shi; Sean R Stowell; Swee Lay Thein; Connie M Westhoff; Trisha E Wong; Elie A Akl
Journal:  Blood Adv       Date:  2020-01-28

Review 4.  Hypoxia-inducible factor (HIF): how to improve osseointegration in hip arthroplasty secondary to avascular necrosis in sickle cell disease.

Authors:  Akintunde George; Marianne Ellis; Harinderjit Singh Gill
Journal:  EFORT Open Rev       Date:  2019-09-10

5.  Total Hip Replacement in Sickle Cell Disease Patients with Avascular Necrosis of Head of Femur: A Retrospective Observational Study.

Authors:  Mohammed Lafi Al-Otaibi; Shah Waliullah; Vineet Kumar
Journal:  Indian J Orthop       Date:  2021-03-28       Impact factor: 1.251

6.  Complex primary hips for total hip replacement surgery at a tertiary institution in Nigeria.

Authors:  Udo Ego Anyaehie; Gabriel Okey Eyichukwu; Cajetan Uwatoronye Nwadinigwe; Amechi Uchenna Katchy
Journal:  SICOT J       Date:  2018-06-12

Review 7.  Total hip arthroplasty in sickle cell disease: a systematic review.

Authors:  Eustathios Kenanidis; Konstantinos Kapriniotis; Panagiotis Anagnostis; Michael Potoupnis; Panayiotis Christofilopoulos; Eleftherios Tsiridis
Journal:  EFORT Open Rev       Date:  2020-03-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.